OpenAI acquires Orchestra Bio, folding it into the Rosalind life-sciences platform for drug-discovery agents

OpenAI announced the acquisition of startup Orchestra Bio for an undisclosed sum, folding the company into its life-sciences platform Rosalind. Rosalind currently includes GPT-Rosalind, which answers biology and chemistry questions, and Rosalind Workbench, which connects scientific data and tools; Orchestra's agent capabilities will layer on top of this platform. Orchestra's agents focus on drug-development coordination: tracking clinical trials, flagging affected timelines when problems such as manufacturing batch failures occur, and presenting next-step options. OpenAI says the goal is to connect scientific discovery with clinical trials, decisions, and follow-up actions to shorten time to market; the piece notes that developing a new drug in the US takes an average of 10 to 15 years, and siloed systems plus repeated back-and-forth between internal and external teams slow progress further. The practical impact lands on pharma research teams working with OpenAI on drug R&D: work that previously required manually monitoring trial progress and syncing across teams can be handed to agents, freeing researchers to focus on judgment and the experiments themselves. OpenAI has previously partnered with Novo Nordisk and Moderna on AI-driven drug research; this acquisition brings coordination-layer tools into its own platform.